OSE Immunotherapeutics Strengthens Collaboration with AbbVie
OSE Immunotherapeutics SA, listed as PARIS:OSE, recently shared important news regarding its partnership with AbbVie on ABBV-230, a monoclonal antibody. This revision marks a significant step in their joint endeavor to develop a treatment aimed at chronic inflammation, which is currently in pre-clinical development.
Details of the Amended Agreement
The newly structured agreement is indicative of both parties' commitment to harness the potential of ABBV-230. Notably, OSE Immunotherapeutics will now lead the early development stages, leveraging their expertise in immunology. This is a strategic move designed to optimize the development process and align the project with the strengths of both companies.
Early Development Leadership
With this amendment, OSE Immunotherapeutics will take charge of preclinical and Phase 1 development initiatives for ABBV-230. The funding for these activities will be fully covered by OSE, contingent on securing the necessary resources, showcasing OSE's confidence in the potential of their program.
Retained Rights for AbbVie
AbbVie still holds exclusive rights for subsequent development phases and commercialization post-Phase 1 transition. This approach allows AbbVie to maintain its pivotal role in the continued evolution of immunological therapies.
Maintaining Commercial Terms
Importantly, all existing commercial agreements remain intact. This includes royalties based on global net sales and milestone payments, ensuring that OSE Immunotherapeutics will retain its economic interests as originally outlined in the partnership agreement.
Adjustment to Milestone Payments
While the adjusted agreement eliminates a previously expected milestone payment tied to the initiation of Phase 1, it enables OSE Immunotherapeutics to qualify for milestone payments as the development progresses, should AbbVie successfully push the candidate through subsequent phases.
The Role of ChemR23
The emphasis on ABBV-230 revolves around its interaction with ChemR23, a receptor that plays a crucial role in managing inflammation. By controlling immune responses and recruitment, it serves as a therapeutic target for various chronic inflammatory diseases, reinforcing the partnership's scientific foundation.
Insights from Leadership
CEO Marc Le Bozec expressed optimism about the amended agreement, stating, "Our collaboration with AbbVie remains a highly valuable endeavor. Taking the reins of early-stage development allows OSE to progress swiftly, utilizing our immunology expertise to its fullest potential." This sentiment echoes the shared vision of advancing innovative therapies for chronic inflammatory conditions.
The Path Ahead for OSE Immunotherapeutics
The strategic partnership formed between OSE Immunotherapeutics and AbbVie aims to foster the rapid development of ABBV-230. This collaborative effort has potential ramifications not only for the involved companies but also for the broader field of therapeutics aimed at inflammatory diseases.
About OSE Immunotherapeutics
OSE Immunotherapeutics is devoted to developing pioneering therapies in immuno-oncology and immuno-inflammation. They actively collaborate with top-tier academic institutions and pharmaceutical enterprises to introduce impactful innovations to the market. Based in Nantes and Paris, they continue to advocate for transformative medical solutions that address pressing patient needs.
Frequently Asked Questions
What is ABBV-230?
ABBV-230 is a monoclonal antibody focused on addressing chronic inflammation and is currently in the pre-clinical development stage.
What changes were made to the partnership with AbbVie?
OSE Immunotherapeutics gained control of early-stage development for ABBV-230, while AbbVie retains rights for later phases following successful Phase 1 completion.
How will OSE finance the early-stage development?
OSE Immunotherapeutics will finance the development of ABBV-230, dependent upon securing adequate funding.
Will AbbVie continue to have a role in the project?
Yes, AbbVie will manage future development and commercialization after the completion of the Phase 1 clinical stage.
What is the significance of ChemR23?
ChemR23 is pivotal in regulating immune responses and is deemed essential in the development of potential therapies for chronic inflammatory diseases.
